$1.55
arrow_drop_up1.97%Key Stats | |
---|---|
Open | $1.50 |
Prev. Close | $1.52 |
EPS | -0.89 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $91.26M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 1.48 | 1.60 |
52 Week Range | 1.14 | 3.53 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -0.89 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024